Material Agreement Form 8 K

Private Placement and Purchase Agreement

On November 13, 2024, Minim, Inc. ("Minim" or the "Company") entered into a Securities Purchase Agreement (the "Purchas Agreement") with Cao Yu, an individual ("Cao"), Hu Bin, an individual, and Youxin Consulting Limited, a Hong Kong company (the "Investors"), whereby, at the closing of the transactions contemplated by the Purchase Agreement (the "Closing"), subject to satisfaction of certain closing conditions, including our stockholders voting in favor of the transaction at a Special Meeting, we will sell, and the Investors will purchase, 1,984,733 shares of the Company's Series B Convertible Preferred Stock, $0.001 par value per share (the "Series B Preferred Stock"), at a price per share of $1.31, for an aggregate purchase price of $2,600,000, subject to the conditions described below, pursuant to the exemptions afforded by the Securities Act of 1933, as amended, and Regulation S thereunder.

The Purchase Agreement contains customary representations, warranties and agreements of the Company and the Investors, limitations and conditions regarding sales of the Purchased Securities or underlying Common Stock, indemnification rights and other obligations of the parties. Furthermore, the Purchase Agreement contains certain conditions to closing, including: (i) a resolution appointing three (3) individuals identified in writing by the Investors to fill the vacancies on the Board of Directors caused by the resignations of all of the members of the Board of Directors as of the Closing Date, (ii) satisfactory evidence that all reasonably required waivers and/or settlement agreements with the Company's creditors, vendors and employees have been received, (iii) the Certificate of Designation of the rights and privileges of the Series B Preferred Stock, (iv) satisfactory evidence that all third-party and governmental consents have been received or sent and not revoked, (v) satisfactory evidence that all holders of equity of the Company with redemption rights or rights to participate in the issuance of Series B Preferred Stock and the shares of Common Stock issuable upon conversion of such shares, if any, have been waived, (vi) satisfactory evidence that all persons with the right to receive severance, retention bonuses, "stay" bonuses, change in control bonuses, transaction bonuses or other similar payments or arrangements have waived any and all rights to receive such bonuses, (vii) satisfactory evidence that identified all related party transactions have been terminated, (viii) satisfactory evidence that all employment agreements have been terminated, (ix) satisfactory evidence that a satisfactory written opinion of the Company's counsel that all of the Series B Preferred Stock and the securities to be purchased pursuant to the Securities Purchase Agreement, dated on even date of the Purchase Agreement, by and among David Elliot Lazar and the Investors are, and the shares of Common Stock underlying the Series B Preferred Stock will be, duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such shares was or would be issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities, (x) the Company's shares be listed on the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or any successors to any of the foregoing by no later than December 31, 2024, and (xi) the approval from the stockholders of the Company of the transactions contemplated by the Purchase Agreement.

The Investors have agreed that they will not engage in or effect, directly or indirectly, any short sales involving the Company's securities or any hedging transaction that transfers the economic risk of ownership of the Common Stock. Additionally, the Board of Directors of the Company unanimously adopted resolutions granting the Investors the right to sell, assign or otherwise transfer either the Series B Preferred Stock (as well as any Common Stock underlying any such Series B Preferred Stock) and/or its rights to acquire the Series B Preferred Stock (as well as any Common Stock underlying any such Securities) pursuant to the Purchase Agreement (the "Securities Purchase Rights"), including by way of option for Purchaser to sell and/or a transferee thereof to purchase, the Securities Purchase Rights.

The terms, rights, obligations and preferences of the Series B Preferred Stock will be set forth in a Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock of the Company (the "Certificate of Designations"). Copies of the Purchase Agreement and the form of Certificate of Designations are attached hereto as Exhibits 10.1 and 4.1, respectively, and are incorporated herein by reference.

This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy any shares of Preferred Stock, nor shall there be any sale of shares of Preferred Stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. The shares sold in the Private Placement do not involve a public offering and have not been registered under the Securities Act of 1933, as amended, in reliance on Regulation S thereunder.